Interestingly, our study also found that GC patients bearing ovarian metastasis with CLDN18-ARHGAP fusion demonstrated resistance to oxaliplatin-based chemotherapy while displaying sensitivity to paclitaxel-based treatment. Here, CLDN18 is linked to gastric cancer.